These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 8446223

  • 1. Erythropoietin versus iron chelators in anaemia and iron overload.
    Vreugdenhil G, van Herpen C, Koene RA.
    Neth J Med; 1993 Feb; 42(1-2):45-7. PubMed ID: 8446223
    [No Abstract] [Full Text] [Related]

  • 2. Clinical spectrum of iron overload, novel uses of iron chelators, and potential treatment of pediatric anemias with erythropoietin. Introduction.
    Cairo MS.
    Am J Pediatr Hematol Oncol; 1990 Feb; 12(1):1-3. PubMed ID: 2178456
    [No Abstract] [Full Text] [Related]

  • 3. The selection and evaluation of new chelating agents for the treatment of iron overload.
    Pitt CG, Gupta G, Estes WE, Rosenkrantz H, Metterville JJ, Crumbliss AL, Palmer RA, Nordquest KW, Hardy KA, Whitcomb DR, Byers BR, Arceneaux JE, Gaines CG, Sciortino CV.
    J Pharmacol Exp Ther; 1979 Jan; 208(1):12-8. PubMed ID: 759605
    [Abstract] [Full Text] [Related]

  • 4. Two novel missense mutations in iron transport protein transferrin causing hypochromic microcytic anaemia and haemosiderosis: molecular characterization and structural implications.
    Athiyarath R, Arora N, Fuster F, Schwarzenbacher R, Ahmed R, George B, Chandy M, Srivastava A, Rojas AM, Sanchez M, Edison ES.
    Br J Haematol; 2013 Nov; 163(3):404-7. PubMed ID: 23888904
    [No Abstract] [Full Text] [Related]

  • 5. [Comparative evaluation of two models of hemosiderosis for analysis of iron chelators].
    Minina LT, Prostakova TM, Meshchano AIu, Kol'tsova GN, Bovenko VN.
    Biull Eksp Biol Med; 1996 Sep; 122(9):359-60. PubMed ID: 8974501
    [No Abstract] [Full Text] [Related]

  • 6. Continuous high-dose intravenous desferrioxamine treatment for iron overload.
    Sidi Y, Shaklai M, Liban E, Pinkhas J.
    Isr J Med Sci; 1981 May; 17(5):348-51. PubMed ID: 7263191
    [Abstract] [Full Text] [Related]

  • 7. Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia.
    Vreugdenhil G, Smeets M, Feelders RA, van Eijk HG.
    Acta Haematol; 1993 May; 89(2):57-60. PubMed ID: 8503244
    [Abstract] [Full Text] [Related]

  • 8. Correction of serious iron overload in a chronic hemodialysis patient by recombinant human erythropoietin and removal of red blood cells: confirmation by follow-up liver biopsy.
    Onoyama K, Nakamura S, Yamamoto M, Kawadoko T, Nanishi F, Komoda T, Murai K, Fujishima M.
    Nephron; 1990 May; 56(3):325-8. PubMed ID: 2077417
    [Abstract] [Full Text] [Related]

  • 9. The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe(3+) values.
    Hider RC, Liu ZD, Piyamongkol S.
    Transfus Sci; 2000 Dec; 23(3):201-9. PubMed ID: 11099896
    [No Abstract] [Full Text] [Related]

  • 10. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias.
    Kwiatkowski JL, Cohen AR.
    Hematol Oncol Clin North Am; 2004 Dec; 18(6):1355-77, ix. PubMed ID: 15511620
    [Abstract] [Full Text] [Related]

  • 11. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.
    Mittelman M, Lugassy G, Merkel D, Tamary H, Sarid N, Rachmilewitz E, Hershko C, MDS Israel Group, Israel Society of Hematology.
    Isr Med Assoc J; 2008 May; 10(5):374-6. PubMed ID: 18605364
    [No Abstract] [Full Text] [Related]

  • 12. Myocardial iron overload in transfusion-dependent pediatric patients with acute leukemia.
    Lutz K, von Komorowski G, Dürken M, Engelhardt R, Dinter DJ.
    Pediatr Blood Cancer; 2008 Nov; 51(5):691-3. PubMed ID: 18623223
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of thalassemia and sickle cell anemia in children].
    Girot R.
    Ann Pediatr (Paris); 1978 Nov; 25(5-6):277-84. PubMed ID: 16114336
    [No Abstract] [Full Text] [Related]

  • 14. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA.
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [Abstract] [Full Text] [Related]

  • 15. Desferrioxamine and transfusional iron overload.
    Lancet; 1978 Mar 04; 1(8062):479-80. PubMed ID: 76025
    [No Abstract] [Full Text] [Related]

  • 16. Oral iron chelators in the treatment of hematologic diseases.
    Hoffbrand AV.
    Clin Adv Hematol Oncol; 2005 Jul 04; 3(7):536-8. PubMed ID: 16167033
    [No Abstract] [Full Text] [Related]

  • 17. [The effect of desferrioxamine on the treatment of transfusion hemosiderosis--with special reference to the method of its administration (authors' transl)].
    Fujiyama N, Nakazawa K.
    Rinsho Ketsueki; 1977 Dec 04; 18(12):1393-400. PubMed ID: 604522
    [No Abstract] [Full Text] [Related]

  • 18. [Quantification of iron level in the liver by MR imaging in patients treated for transfusion siderosis].
    Jensen PD, Jensen FT, Christensen T, Ellegard J.
    Ugeskr Laeger; 1998 Feb 16; 160(8):1168-74. PubMed ID: 9492628
    [Abstract] [Full Text] [Related]

  • 19. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
    Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E.
    Eur J Haematol; 2007 Jun 16; 78(6):540-2. PubMed ID: 17391307
    [Abstract] [Full Text] [Related]

  • 20. Iron: The fifth horseman of the apocalypse?
    DeLoughery TG.
    Am J Hematol; 2009 May 16; 84(5):263-4. PubMed ID: 19358299
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.